deferiprone has been researched along with Acquired Metabolic Diseases, Brain in 1 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kuo, PH | 1 |
| Kuo, SH | 1 |
| Lo, RY | 1 |
1 other study available for deferiprone and Acquired Metabolic Diseases, Brain
| Article | Year |
|---|---|
Deferiprone Reduces Hemosiderin Deposition in Superficial Siderosis.
Topics: Brain Diseases, Metabolic; Deferiprone; Female; Hemosiderin; Hemosiderosis; Humans; Iron Chelating A | 2017 |